Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 007

Next Previous
Drug Profile

TAK 007

Alternative Names: Anti-CD19 CAR NK-cell therapy - Takeda/The University of Texas MD Anderson Cancer Center; Anti-CD19 chimeric antigen receptor NK-cell therapy - Takeda/The University of Texas MD Anderson Cancer Center; TAK-007

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II B-cell lymphoma
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 03 Apr 2025 Takeda withdraws a phase Ib trial in Lupus nephritis and Systemic scleroderma (Treatment-resistant) in USA (IV, Infusion) prior to enrollment due to business decision (NCT06377228)
  • 07 Dec 2024 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Non-Hodgkin Lymphoma presented at the at the 66th American Society of Hematology Annual Meeting and Exposition ( ASH-Hem-2024)
  • 22 Apr 2024 Takeda plans a phase Ib trial for Lupus nephritis (In adults, In the elderly) in USA (IV, Infusion), in November 2024 (NCT06377228)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top